Novo Nordisk A/S
NONOF
$65.14
$1.141.78%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.10B | 4.03B | 4.02B | 2.89B | 3.70B |
| Total Depreciation and Amortization | 539.99M | 11.58M | 316.82M | 453.79M | 314.07M |
| Total Amortization of Deferred Charges | -- | 36.44M | -- | -- | -- |
| Total Other Non-Cash Items | 1.15B | -2.18B | 3.78B | 2.63B | -530.30M |
| Change in Net Operating Assets | -2.32B | -140.20M | -1.66B | 1.31B | -1.40B |
| Cash from Operations | 3.47B | 1.76B | 6.46B | 7.29B | 2.08B |
| Capital Expenditure | -1.89B | -2.30B | -1.79B | -1.51B | -1.23B |
| Sale of Property, Plant, and Equipment | -- | -142.90K | 147.40K | -- | -- |
| Cash Acquisitions | -- | -11.65B | 0.00 | -96.39M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 952.03M | 911.93M | -1.29B | -1.38B | 1.81B |
| Cash from Investing | -941.31M | -13.04B | -3.08B | -2.99B | 576.02M |
| Total Debt Issued | 27.36B | 44.76B | 119.00M | 34.51B | -- |
| Total Debt Repaid | -12.03B | -433.00M | -532.00M | -5.05B | -317.00M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1.39B | -7.49B | -2.41B | -7.45B | -2.84B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.98B | 0.00 | -2.30B | 0.00 | -4.16B |
| Other Financing Activities | 26.78B | -- | -- | -5.33B | 5.33B |
| Cash from Financing | 768.93M | 5.26B | -2.71B | 2.41B | -3.84B |
| Foreign Exchange rate Adjustments | -12.13M | 102.47M | -51.28M | 6.06M | 6.41M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.28B | -5.91B | 618.46M | 6.71B | -1.17B |